MA54859A - Composés 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activité inhibitrice de cdk2 - Google Patents

Composés 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activité inhibitrice de cdk2

Info

Publication number
MA54859A
MA54859A MA054859A MA54859A MA54859A MA 54859 A MA54859 A MA 54859A MA 054859 A MA054859 A MA 054859A MA 54859 A MA54859 A MA 54859A MA 54859 A MA54859 A MA 54859A
Authority
MA
Morocco
Prior art keywords
carbonylamino
cyclopentyl
inhibiting activity
pyrazole compounds
cdk2
Prior art date
Application number
MA054859A
Other languages
English (en)
Inventor
Douglas Carl Behenna
Kevin Daniel Freeman-Cook
Robert Louis Hoffman
Asako Nagata
Sacha Ninkovic
Scott Channing Sutton
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA54859A publication Critical patent/MA54859A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054859A 2019-01-31 2020-01-28 Composés 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activité inhibitrice de cdk2 MA54859A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799455P 2019-01-31 2019-01-31
US202062959042P 2020-01-09 2020-01-09

Publications (1)

Publication Number Publication Date
MA54859A true MA54859A (fr) 2022-05-04

Family

ID=69467606

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054859A MA54859A (fr) 2019-01-31 2020-01-28 Composés 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activité inhibitrice de cdk2

Country Status (23)

Country Link
US (3) US11014911B2 (fr)
EP (1) EP3917913A2 (fr)
JP (2) JP7094456B2 (fr)
KR (1) KR20210121186A (fr)
CN (1) CN113330000A (fr)
AU (2) AU2020213761C1 (fr)
BR (1) BR112021012635A2 (fr)
CA (1) CA3128155C (fr)
CL (1) CL2021001991A1 (fr)
CO (1) CO2021009806A2 (fr)
CR (1) CR20210415A (fr)
CU (1) CU20210065A7 (fr)
DO (1) DOP2021000154A (fr)
EC (1) ECSP21055158A (fr)
IL (1) IL284589A (fr)
MA (1) MA54859A (fr)
MX (1) MX2021009276A (fr)
PE (1) PE20212250A1 (fr)
PH (1) PH12021551529A1 (fr)
SG (1) SG11202106896TA (fr)
TW (1) TWI738197B (fr)
UY (1) UY38553A (fr)
WO (1) WO2020157652A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3917913A2 (fr) * 2019-01-31 2021-12-08 Pfizer Inc. Composés 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activité inhibitrice de cdk2
CA3189632A1 (fr) * 2020-07-20 2022-01-27 Pfizer Inc. Polytherapie
WO2022018667A1 (fr) 2020-07-24 2022-01-27 Pfizer Inc. Polythérapies utilisant des inhibiteurs de cdk2 et de cdc25a
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022135365A1 (fr) * 2020-12-22 2022-06-30 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Inhibiteurs de kinase de cyclopentane disubstitués
TW202229268A (zh) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｃｄｋ２抑制劑及其製備方法
US20240076287A1 (en) * 2020-12-24 2024-03-07 Pfizer Inc. Solid forms of a cdk2 inhibitor
WO2022149057A1 (fr) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
WO2022206888A1 (fr) * 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Inhibiteurs de cdk2 et leur utilisation
WO2022236058A1 (fr) * 2021-05-07 2022-11-10 Kymera Therapeutics, Inc. Agents de dégradation de cdk2 et leurs utilisations
CN117897384A (zh) 2021-06-28 2024-04-16 缆图药品公司 Cdk2抑制剂
TW202317564A (zh) * 2021-07-01 2023-05-01 大陸商上海拓界生物醫藥科技有限公司 Cdk2抑制劑及其製備方法和用途
CA3229067A1 (fr) * 2021-10-05 2023-04-13 Genentech, Inc. Inhibiteurs de cyclopentylpyrazole cdk2
TW202325280A (zh) * 2021-11-09 2023-07-01 大陸商上海拓界生物醫藥科技有限公司 一種胺基吡唑衍生物及其製備方法和用途
WO2023092088A1 (fr) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Inhibiteurs de cdk2 et leurs procédés de fabrication et d'utilisation
WO2023100131A1 (fr) 2021-12-02 2023-06-08 Pfizer Inc. Méthodes et schémas posologiques comprenant un inhibiteur de cdk2 pour le traitement du cancer
WO2023100134A1 (fr) 2021-12-02 2023-06-08 Pfizer Inc. Méthodes et schémas posologiques comprenant un inhibiteur de cdk2 et un inhibiteur de cdk4 pour le traitement du cancer
WO2023168686A1 (fr) * 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Cyclopentanes substitués utilisés en tant qu'inhibiteurs de cdk2
WO2023116884A1 (fr) * 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Inhibiteurs de cdk2 et leur utilisation
WO2023141852A1 (fr) * 2022-01-27 2023-08-03 益方生物科技(上海)股份有限公司 Inhibiteurs de la cdk2, leur procédé de préparation et leur utilisation
WO2023160572A1 (fr) * 2022-02-24 2023-08-31 楚浦创制（武汉）医药科技有限公司 Dérivé de pyrazole, composition pharmaceutique et utilisation
WO2023208143A1 (fr) * 2022-04-28 2023-11-02 正大天晴药业集团股份有限公司 Dérivé d'ester de cyclopentanol substitué par pyrazole et son utilisation
WO2023239629A1 (fr) * 2022-06-06 2023-12-14 Plexium, Inc. Composés et compositions pharmaceutiques qui dégradent cdk2
TW202400152A (zh) * 2022-06-16 2024-01-01 美商昂勝醫療科技股份有限公司 苯胺基-吡唑衍生物、其組成物及方法
WO2024035830A1 (fr) * 2022-08-11 2024-02-15 Relay Therapeutics, Inc. Formes solides d'un inhibiteur de cdk
WO2024046443A1 (fr) * 2022-09-01 2024-03-07 Nutshell Biotech (Shanghai) Co., Ltd. Composés macrocycliques utilisés en tant qu'inhibiteurs sélectifs de cdk
WO2024056019A1 (fr) * 2022-09-15 2024-03-21 Beigene, Ltd. Composés bicycliques utilisés en tant qu'inhibiteurs de cdk
WO2024066981A1 (fr) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 Dérivés de pyrazole deutérés, composition pharmaceutique, utilisation et procédé de préparation
WO2024104455A1 (fr) * 2022-11-17 2024-05-23 山东绿叶制药有限公司 Inhibiteur de cdk2, son procédé de préparation et son utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
OA12368A (en) 2000-08-31 2004-04-13 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors.
US20020103185A1 (en) 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
MXPA05001590A (es) 2002-08-09 2005-05-23 Astrazeneca Ab Compuestos que tienen actividad en los receptores metabotropicos de glutamato.
EP1536790A2 (fr) 2002-08-09 2005-06-08 AstraZeneca AB Oxidiazoles comme modulateurs du recepteur-5 metabotropique du glutamate
EP1689721B1 (fr) * 2003-11-26 2010-07-14 Pfizer Products Inc. Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
WO2005077345A1 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Composes pour le traitement de la maladie du reflux gastro-oesophagien
WO2005077368A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique iii
WO2005077373A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique ii
MX2007003377A (es) 2004-09-23 2007-05-10 Pfizer Prod Inc Agonistas del receptor de trombopoyetina.
EP2300004A4 (fr) 2008-05-15 2012-05-30 Univ Duke Compositions et procédés ayant trait aux composés activant le facteur de transcription de choc thermique et cibles correspondantes
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
WO2012129562A2 (fr) 2011-03-24 2012-09-27 The Scripps Research Institute Composés et procédés pour l'induction de la chondrogenèse
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
EP3917913A2 (fr) * 2019-01-31 2021-12-08 Pfizer Inc. Composés 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activité inhibitrice de cdk2

Also Published As

Publication number Publication date
CA3128155C (fr) 2023-09-19
JP2022513534A (ja) 2022-02-08
WO2020157652A2 (fr) 2020-08-06
US11014911B2 (en) 2021-05-25
PE20212250A1 (es) 2021-11-24
UY38553A (es) 2020-08-31
SG11202106896TA (en) 2021-08-30
US20200247784A1 (en) 2020-08-06
ECSP21055158A (es) 2021-08-31
TW202043214A (zh) 2020-12-01
US20210269425A1 (en) 2021-09-02
WO2020157652A8 (fr) 2021-08-19
DOP2021000154A (es) 2021-08-31
US11773082B2 (en) 2023-10-03
CL2021001991A1 (es) 2022-04-08
AU2023200842B2 (en) 2024-06-13
WO2020157652A3 (fr) 2020-09-10
US20210261530A1 (en) 2021-08-26
PH12021551529A1 (en) 2022-02-28
BR112021012635A2 (pt) 2021-12-14
JP2022120200A (ja) 2022-08-17
CR20210415A (es) 2021-08-26
EP3917913A2 (fr) 2021-12-08
AU2023200842A1 (en) 2023-03-16
CN113330000A (zh) 2021-08-31
TWI738197B (zh) 2021-09-01
MX2021009276A (es) 2021-08-24
US11718603B2 (en) 2023-08-08
IL284589A (en) 2021-08-31
JP7094456B2 (ja) 2022-07-01
AU2020213761C1 (en) 2023-08-10
CO2021009806A2 (es) 2021-08-09
KR20210121186A (ko) 2021-10-07
CA3128155A1 (fr) 2020-08-06
AU2020213761B2 (en) 2022-11-17
AU2020213761A1 (en) 2021-07-15
CU20210065A7 (es) 2022-04-07

Similar Documents

Publication Publication Date Title
MA54859A (fr) Composés 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activité inhibitrice de cdk2
AR119765A1 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
DK4065575T3 (da) Substituerede tricycliske forbindelser
MA56008A (fr) Composés et compositions pour traiter des états associés à une activité de nlrp
MA55064A (fr) Composés utilisés comme inhibiteurs de kinase
MA52948A (fr) Composés
MA44085A (fr) Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants
MA51669A (fr) Composés
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
MA53003A (fr) Composés
ES2972949T3 (es) Compuestos de azolamida plaguicidamente activos
MA53755A (fr) Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité comme agonist de taar
DK4018074T3 (da) Borebrøndindretning
DE102020112518B8 (de) Toner
MA52348A (fr) Composés hétéroaromatiques ayant une activité contre vrs
DK3797662T3 (da) Vippedyvel
DK3900819T3 (da) Opstrømsreaktor
MA52946A (fr) Composés
MA51221A (fr) Composés de pyrazolopyridinone
MA51450A (fr) Orge ayant une activité enzymatique hydrolytique accrue
MA54286A (fr) Autres composés hétéroaromatiques ayant une activité contre le vrs
MA56058A (fr) Composés tricycliques
IT201900020970A1 (it) Composti diarilossibenzoeterodiazolici disostituiti con gruppi tienotiofenici
MA50561A (fr) Composés inhibiteurs de btk